Neuroendocrine gastric carcinoma expressing somatostatin: a highly malignant, rare tumor.
Poorly differentiated gastric neuroendocrine carcinomas, although rare, deserve particular attention, as they are aggressive and have an extremely poor prognosis. In this report we describe a gastric neuroendocrine carcinoma with rapidly fatal outcome. Immunohistological staining of the resected specimens revealed that the tumor was an endocrine carcinoma. The tumor disclosed intense immunoreactivity to pan-neuroendocrine markers and diffuse somatostatin immunoreactivity. There were no psammoma bodies and no demonstrable association with von Recklinghausen's neurofibromatosis. In the gastrointestinal tract, neuroendocrine tumors producing predominantly somatostatin have been described only in the duodenum. To the best of our knowledge, the present report is the second case report of a neuroendocrine gastric carcinoma expressing diffusely somatostatin as the only neuroendocrine regulatory peptide.
Waisberg
Jaques
J
Department of Surgery, Faculty of Medicine of ABC, Santo André, Braz. jaqueswaisberg@uol.com.br
de Matos
Leandro Luongo
LL
do Amaral Antonio Mader
Ana Maria
AM
Pezzolo
Sergio
S
Eher
Esmeralda Miristene
EM
Capelozzi
Vera Luiza
VL
Speranzini
Manlio Basilio
MB
D000368:Aged; D018278:Carcinoma, Neuroendocrine / Q000737:chemistry* / Q000235:genetics / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D011379:Prognosis; D013004:Somatostatin / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000473:pathology; D015996:Survival Rate
D013004:Somatostatin